Ici 200880

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 597827

CAS#: 105080-50-0

Description: Ici 200880 is a synthetic peptide inhibitor of human neutrophil elastase.

Chemical Structure

Ici 200880
CAS# 105080-50-0

Theoretical Analysis

MedKoo Cat#: 597827
Name: Ici 200880
CAS#: 105080-50-0
Chemical Formula: C30H34ClF3N4O7S
Exact Mass: 686.1789
Molecular Weight: 687.12
Elemental Analysis: C, 52.44; H, 4.99; Cl, 5.16; F, 8.29; N, 8.15; O, 16.30; S, 4.67

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Ici 200880; Ici-200880; Ici200880; Ici 200,880; Ic-200,880; Ici200,880;

IUPAC/Chemical Name: N1-((4-chlorophenyl)sulfonyl)-N4-((2S)-3-methyl-1-oxo-1-((2S)-2-((1,1,1-trifluoro-4-methyl-2-oxopentan-3-yl)carbamoyl)pyrrolidin-1-yl)butan-2-yl)terephthalamide


InChi Code: InChI=1S/C30H34ClF3N4O7S/c1-16(2)23(25(39)30(32,33)34)35-28(42)22-6-5-15-38(22)29(43)24(17(3)4)36-26(40)18-7-9-19(10-8-18)27(41)37-46(44,45)21-13-11-20(31)12-14-21/h7-14,16-17,22-24H,5-6,15H2,1-4H3,(H,35,42)(H,36,40)(H,37,41)/t22-,23?,24-/m0/s1

SMILES Code: O=C(NC(C(C)C)C(C(F)(F)F)=O)[C@H]1N(C([C@H](C(C)C)NC(C2=CC=C(C(NS(=O)(C3=CC=C(Cl)C=C3)=O)=O)C=C2)=O)=O)CCC1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

Preparing Stock Solutions

The following data is based on the product molecular weight 687.12 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Williams JC, Stein RL, Giles RE, Krell RD. Biochemistry and pharmacology of ICI 200,880, a synthetic peptide inhibitor of human neutrophil elastase. Ann N Y Acad Sci. 1991;624:230-43. PubMed PMID: 2064224.

2: Davis PC, Wildonger RA, Veale HS. A specific radioimmunoassay for the measurement of ICI 200,880, an elastase inhibitor, in human serum. J Pharm Biomed Anal. 1993 Jul;11(7):549-56. PubMed PMID: 8399528.

3: Williams JC, Falcone RC, Knee C, Stein RL, Strimpler AM, Reaves B, Giles RE, Krell RD. Biologic characterization of ICI 200,880 and ICI 200,355, novel inhibitors of human neutrophil elastase. Am Rev Respir Dis. 1991 Oct;144(4):875-83. PubMed PMID: 1928965.

4: Mehta JL, Nichols WW, Nicolini FA, Hendricks J, Donnelly WH, Saldeen TG. Neutrophil elastase inhibitor ICI 200,880 protects against attenuation of coronary flow reserve and myocardial dysfunction following temporary coronary artery occlusion in the dog. Cardiovasc Res. 1994 Jul;28(7):947-56. PubMed PMID: 7954605.

5: Tiefenbacher CP, Ebert M, Niroomand F, Batkai S, Tillmanns H, Zimmermann R, Kübler W. Inhibition of elastase improves myocardial function after repetitive ischaemia and myocardial infarction in the rat heart. Pflugers Arch. 1997 Mar;433(5):563-70. PubMed PMID: 9049140.

6: Turino GM, Davies P, Dunlap R, Krell RD, Maycock AL, Rennard S, Stockley RA. Selection of a therapeutic agent for the treatment of chronic obstructive pulmonary disease in smokers. Ann N Y Acad Sci. 1991 Dec 31;624 Suppl:23-30. PubMed PMID: 1686162.

7: Pacholok SG, Davies P, Dorn C, Finke P, Hanlon WA, Mumford RA, Humes JL. Formation of polymorphonuclear leukocyte elastase: alpha 1 proteinase inhibitor complex and A alpha (1-21) fibrinopeptide in human blood stimulated with the calcium ionophore A23187. A model to characterize inhibitors of polymorphonuclear leukocyte elastase. Biochem Pharmacol. 1995 May 17;49(10):1513-20. PubMed PMID: 7763294.

8: Bernstein PR, Gomes BC, Kosmider BJ, Vacek EP, Williams JC. Nonpeptidic inhibitors of human leukocyte elastase. 6. Design of a potent, intratracheally active, pyridone-based trifluoromethyl ketone. J Med Chem. 1995 Jan 6;38(1):212-5. PubMed PMID: 7837235.

9: Nicolini FA, Mehta JL, Nichols WW, Donnelly WH, Luostarinen R, Saldeen TG. Leukocyte elastase inhibition and t-PA-induced coronary artery thrombolysis in dogs: beneficial effects on myocardial histology. Am Heart J. 1991 Nov;122(5):1245-51. PubMed PMID: 1950986.

10: Brown FJ, Andisik DW, Bernstein PR, Bryant CB, Ceccarelli C, Damewood JR Jr, Edwards PD, Earley RA, Feeney S, Green RC, et al. Design of orally active, non-peptidic inhibitors of human leukocyte elastase. J Med Chem. 1994 Apr 29;37(9):1259-61. PubMed PMID: 8176703.